Modeling the Health Impact and Cost-Effectiveness of a Combined Schoolgirl HPV Vaccination and Cervical Cancer Screening Program in Guangdong Province, China

Overview

Journal Children (Basel)

Specialty Health Services

Date 2024 Jan 23

PMID 38255416

Authors

Yating Huang

Dantao Zhang

Lihua Yin

Jianguo Zhao

Zhifeng Li

Jing Lu

Xiaoming Zhang

Chenggang Wu

Wei Wu

Affiliations

Soon will be listed here.

Abstract

Low human papillomavirus (HPV) vaccine uptake is a key barrier to cervical cancer elimination. We aimed to evaluate the health impact and cost-effectiveness of introducing different HPV vaccines into immunization programs and scaling up the screening program in Guangdong. We used a dynamic compartmental model to estimate the impact of intervention strategies during 2023-2100. We implemented the incremental cost-effectiveness ratio (ICER) in costs per averted disability-adjusted life year (DALY) as an indicator to assess the effectiveness of the intervention. We used an age-standardized incidence of 4 cases per 100,000 women as the threshold for the elimination of cervical cancer. Compared with the status quo, scaling up cervical cancer screening coverage alone would prevent 215,000 (95% CI: 205,000 to 227,000) cervical cancer cases and 49,000 (95% CI: 48,000 to 52,000) deaths during 2023-2100. If the coverage of vaccination reached 90%, domestic two-dose 2vHPV vaccination would be more cost-effective than single-dose and two-dose 9vHPV vaccination. If Guangdong introduced domestic two-dose 2vHPV vaccination at 90% coverage for schoolgirls from 2023 and increased the screening coverage, cervical cancer would be eliminated by 2049 (95% CI 2047 to 2051). Introducing two doses of domestic 2vHPV vaccination for schoolgirls and expanding cervical cancer screening is estimated to be highly cost-effective to accelerate the elimination of cervical cancer in Guangdong.

References

Salomon J, Vos T, Hogan D, Gagnon M, Naghavi M, Mokdad A . Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2129-43. PMC: 10782811. DOI: 10.1016/S0140-6736(12)61680-8. View

Wang R, Pan W, Jin L, Huang W, Li Y, Wu D . Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2019; 471:88-102. DOI: 10.1016/j.canlet.2019.11.039. View

You T, Zhao X, Hu S, Gao M, Liu Y, Zhang Y . Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: A modelling study. EClinicalMedicine. 2023; 56:101789. PMC: 9813696. DOI: 10.1016/j.eclinm.2022.101789. View

Markowitz L, Drolet M, Perez N, Jit M, Brisson M . Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine. 2018; 36(32 Pt A):4806-4815. DOI: 10.1016/j.vaccine.2018.01.057. View

Levin C, Sharma M, Olson Z, Verguet S, Shi J, Wang S . An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Vaccine. 2015; 33(24):2830-41. DOI: 10.1016/j.vaccine.2015.02.052. View

Gao M, Hu S, Zhao X, You T, Jit M, Liu Y . Health and economic impact of delaying large-scale HPV vaccination and screening implementation on cervical cancer in China: a modelling study. Lancet Reg Health West Pac. 2023; 36:100768. PMC: 10398607. DOI: 10.1016/j.lanwpc.2023.100768. View

Murray C, Vos T, Lozano R, Naghavi M, Flaxman A, Michaud C . Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2197-223. DOI: 10.1016/S0140-6736(12)61689-4. View

Xia C, Xu X, Zhao X, Hu S, Qiao Y, Zhang Y . Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Med. 2021; 19(1):62. PMC: 7927373. DOI: 10.1186/s12916-021-01930-9. View

Catarino R, Schafer S, Vassilakos P, Petignat P, Arbyn M . Accuracy of combinations of visual inspection using acetic acid or lugol iodine to detect cervical precancer: a meta-analysis. BJOG. 2017; 125(5):545-553. DOI: 10.1111/1471-0528.14783. View

10.

. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer. Saudi Med J. 2022; 43(5):538. PMC: 9280593. View

11.

Kreimer A, Sampson J, Porras C, Schiller J, Kemp T, Herrero R . Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. J Natl Cancer Inst. 2020; 112(10):1038-1046. PMC: 7566548. DOI: 10.1093/jnci/djaa011. View

12.

Jing L, Zhong X, Zhong Z, Huang W, Liu Y, Yang G . Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women. Sex Transm Dis. 2015; 41(12):732-8. DOI: 10.1097/OLQ.0000000000000201. View

13.

Ji L, Chen M, Yao L . Strategies to eliminate cervical cancer in China. Front Oncol. 2023; 13:1105468. PMC: 10273099. DOI: 10.3389/fonc.2023.1105468. View

14.

Choi H, Jit M, Leung G, Tsui K, Wu J . Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis. BMC Med. 2018; 16(1):127. PMC: 6097427. DOI: 10.1186/s12916-018-1118-3. View

15.

Schmeink C, Massuger L, Lenselink C, Quint W, Witte B, Berkhof J . Prospective follow-up of 2,065 young unscreened women to study human papillomavirus incidence and clearance. Int J Cancer. 2012; 133(1):172-81. DOI: 10.1002/ijc.27986. View

16.

Burger E, Campos N, Sy S, Regan C, Kim J . Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine. 2018; 36(32 Pt A):4823-4829. PMC: 6066173. DOI: 10.1016/j.vaccine.2018.04.061. View

17.

Whitworth H, Gallagher K, Howard N, Mounier-Jack S, Mbwanji G, Kreimer A . Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. 2019; 38(6):1302-1314. DOI: 10.1016/j.vaccine.2019.12.017. View

18.

Levin C, Sellors J, Shi J, Ma L, Qiao Y, Ortendahl J . Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer. 2010; 127(6):1404-11. DOI: 10.1002/ijc.25150. View

19.

Zhao X, Hu S, Hu J, Wang H, Wen T, Feng Y . Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward. Infect Dis Poverty. 2023; 12(1):86. PMC: 10512493. DOI: 10.1186/s40249-023-01136-6. View

20.

Basu P, Malvi S, Joshi S, Bhatla N, Muwonge R, Lucas E . Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021; 22(11):1518-1529. PMC: 8560643. DOI: 10.1016/S1470-2045(21)00453-8. View